Jill Feldman: The true art of oncology is understanding that the right approach/treatment MUST align with the soul, preferences and dreams of the patient (and fam) in front of you.

Jill Feldman retwitted a post by Stephen V.Liu on X/Twitter, adding:

“The true art of oncology is understanding that the right approach/treatment doesn’t have to always align perfectly with protocols and guidelines, but it MUST align with the soul, preferences and dreams of the patient (and fam) in front of you.”

Quoting Stephen V.Liu’s post:

“No one better to start the conference than Jill Feldman – helping us learn from the patients’ lived experiences. Stresses empathetic communication, remember the people behind the endpoints and “tolerable” is a relative term!”

Source: Jill Feldman/Twitter and Stephen V.Liu/Twitter.

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.